About: Neuropathix

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Neuropathix Goto Sponge NotDistinct Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/5ZZ6KjtAbD

Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics. In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019 along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol. Neuropathix family of monotherapeutic small molecul

Attributes	Values
rdf:type	Thing company schema:Organization dul:Agent dul:SocialPerson agent wikidata:Q24229398 Organization Business enterprise organisation
rdfs:label	Neuropathix (en)
rdfs:comment	Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics. In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019 along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol. Neuropathix family of monotherapeutic small molecul (en)
foaf:name	Neuropathix Inc. (en)
foaf:homepage	http://neuropathix.com/
name	Neuropathix Inc. (en)
foaf:depiction
location	Doylestown, Pennsylvania
dcterms:subject	Corporate social responsibility Cannabis research Health care companies based in Pennsylvania Social responsibility Companies based in Bucks County, Pennsylvania Social responsibility organizations Pharmaceutical companies of the United States
Wikipage page ID	67135363 (xsd:integer)
Wikipage revision ID	1067322970 (xsd:integer)
Link from a Wikipage to another Wikipage	Cannabidiol Mitochondrial disease Corporate social responsibility Anti-inflammatory Inflammation Public company Neurodegeneration Concussion Chemotherapy-induced peripheral neuropathy Neuropathic pain Small molecule Cannabis research Pharmaceutical industry Health care companies based in Pennsylvania Social responsibility Companies based in Bucks County, Pennsylvania Doylestown, Pennsylvania Chronic pain Chronic traumatic encephalopathy KLS-13019 Hepatic encephalopathy Social responsibility organizations Pharmaceutical companies of the United States Biopharmaceutical Biotechnology National Institute of Neurological Disorders and Stroke National Institutes of Health Pain management Neuroprotection Thoma Kikis Oxidative stress Kannalife CIPN
Link from a Wikipage to an external page	http://neuropathix.com/ http://www.neuropathix.com/
sameAs	Neuropathix Neuropathix
dbp:wikiPageUsesTemplate	dbt:Patent dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:OTCQB
thumbnail	wiki-commons:Special:FilePath/Neuropathix-logo.png?width=300
assets	Patents , (en)
founders	Dean Petkanas, Thoma Kikis (en)
homepage	http://neuropathix.com/
industry	Pharmaceutical industry Biotechnology
location	Doylestown, Pennsylvania
logo	260 (xsd:integer)
type	Public company
has abstract	Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics. In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019 along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol. Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders. In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH). The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain. Neuropathix is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE. (en)
prov:wasDerivedFrom	wikipedia-en:Neuropathix?oldid=1067322970&ns=0
page length (characters) of wiki page	5693 (xsd:nonNegativeInteger)
founded by	Thoma Kikis
industry	Pharmaceutical industry
type	Public company
foaf:isPrimaryTopicOf	wikipedia-en:Neuropathix
is Link from a Wikipage to another Wikipage of	KLS-13019 KannaLife
is foaf:primaryTopic of	wikipedia-en:Neuropathix

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software